{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:52Z","timestamp":1791331252808,"version":"4.3.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,7,4]],"date-time":"2015-07-04T00:00:00Z","timestamp":1435968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s12185-015-1826-9","type":"journal-article","created":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T01:23:00Z","timestamp":1435886580000},"page":"304-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits"],"prefix":"10.1007","volume":"102","author":[{"given":"Hirohisa","family":"Nakamae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sogabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuru","family":"Kanakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,4]]},"reference":[{"key":"1826_CR1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290\u20133.","journal-title":"Nature"},{"key":"1826_CR2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330\u201340.","journal-title":"N Engl J Med"},{"key":"1826_CR3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28\u201337.","journal-title":"Blood"},{"key":"1826_CR4","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","volume":"111","author":"H Kantarjian","year":"2008","unstructured":"Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008;111:1774\u201380.","journal-title":"Blood"},{"key":"1826_CR5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","volume":"107","author":"S Branford","year":"1999","unstructured":"Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999;107:587\u201399.","journal-title":"Br J Haematol"},{"key":"1826_CR6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2006;108:1809\u201320.","journal-title":"Blood"},{"key":"1826_CR7","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B, et al. Nilotinib in Imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542\u201351.","journal-title":"N Engl J Med"},{"key":"1826_CR8","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following Imatinib resistance and intolerance. Blood. 2007;110:3540\u20136.","journal-title":"Blood"},{"key":"1826_CR9","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in Imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"1826_CR10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myeloid leukemia in chronic phase with resistance or intolerance to Imatinib. Leukemia. 2008;22:1200\u20136.","journal-title":"Leukemia"},{"key":"1826_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-013-1470-1","volume":"99","author":"S Fujisawa","year":"2014","unstructured":"Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, et al. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): subset analysis of the DASISION trail with 2-year follow-up. Int J Hematol. 2014;99:141\u201353.","journal-title":"Int J Hematol"},{"key":"1826_CR12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperiey JF, et al. European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"1826_CR13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley M, et al. Frequency of major molecular responses to Imatinib or Interferon alfa plus Cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423\u201332.","journal-title":"N Engl J Med"},{"key":"1826_CR14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"Mahon Fx","year":"2010","unstructured":"Fx Mahon, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"1826_CR15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O\u2019Hare","year":"2012","unstructured":"O\u2019Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nature Rev Cancer. 2012;12:513\u201326.","journal-title":"Nature Rev Cancer"},{"key":"1826_CR16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10147-011-0328-x","volume":"17","author":"C Yoshida","year":"2012","unstructured":"Yoshida C, Fletcher L, Ohashi K, Wakita H, Kumagai T, Shiseki M, et al. harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol. 2012;17:584\u20139.","journal-title":"Int J Clin Oncol"},{"key":"1826_CR17","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe against cancer program. Leukemia. 2003;17:2318\u201357.","journal-title":"Leukemia"},{"key":"1826_CR18","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, Coutre PL, Etienne G, Lobo C, et al. Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"1826_CR19","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"1826_CR20","unstructured":"Tholen DW, Linnet K, Kondratovich M, Armbruster DA, Garrett PE, Jones RL et al. Protocols for determination of limits of detection and limits of quantitation; approved guideline, EP17-A, 2nd ed, vol 24, no 34. Wayne: NCCLS publication; 2004."},{"key":"1826_CR21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.leu.2402392","volume":"16","author":"SE Langabeer","year":"2002","unstructured":"Langabeer SE, Gale RE, Harvey RC, Cook RW, Mackinnon S, Linch DC. Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia. Leukemia. 2002;16:393\u20139.","journal-title":"Leukemia"},{"key":"1826_CR22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1101\/gr.6.10.986","volume":"6","author":"CA Heid","year":"1996","unstructured":"Heid CA, Stevebs J, Livak KJ. Real time quantitative PCR. Genome Res. 1996;6:986\u201394.","journal-title":"Genome Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1826-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-015-1826-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1826-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:11:25Z","timestamp":1559437885000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-015-1826-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,4]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1007\/s12185-015-1826-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,4]]}}}